Skip to main content
Ariel Lopez Chavez, MD, Oncology, Pittsburgh, PA, Allegheny General Hospital

ArielLopez ChavezMDMS(He/Him)

Oncology Pittsburgh, PA

Director of Precision Medicine and Developmental Therapeutics at the Allegheny Health Network Cancer Institute

Dr. Lopez Chavez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lopez Chavez's full profile

Already have an account?

Summary

  • Board certified medical oncologist specializing in thoracic malignancies. Trained at the National Cancer Institute and then lead the lung cancer clinical and research programs at the Oregon Health and Science University's Knight Cancer Institute in Portland, OR and at the University of Miami, Sylvester Comprehensive Cancer Center. From 2015 to 2022 I was a Medical Director and Global Head of Oncology Strategic Innovations at Roche / Genentech.

    I am currently the Director of Precision Medicine and Developmental Therapeutics at the Allegheny Health Network Cancer Institute.

Clinical Expertise

  • Lung cancer, Personalized medicine, Thoracic oncology, Developmental Therapeutics, General medical oncology, Precision Medicine

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
  • Universidad Nacional Autonoma de Mexico
    Universidad Nacional Autonoma de MexicoMS, Neurobiology, 2002 - 2005
  • Other
    OtherClass of 2002
  • Centro de Computacion Professional de Mexico
    Centro de Computacion Professional de MexicoBachelor's, Computer Programming, 1993 - 1995

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2017 - 2025
  • CA State Medical License
    CA State Medical License 2016 - 2025
  • PA State Medical License
    PA State Medical License 2005 - 2024
  • OR State Medical License
    OR State Medical License 2010 - 2021
  • FL State Medical License
    FL State Medical License 2014 - 2018
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Publications & Presentations

PubMed

Journal Articles

  • Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial  
    Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Be..., J Clin Oncol, 1/9/2015
  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):...  
    Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zal..., Lancet Oncol, 1/1/2015
  • Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer  
    Sullivan DR, Ganzini L, Lopez-Chavez A, Slatore CG, Psycho-Oncology, 1/28/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-sma...
    David E. Gerber, Suresh S. Ramalingam, Daniel Morgensztern, Ronan Joseph Kelly, Timothy Francis Burns, Ariel Lopez-Chavez, David R. Spigel, Ahmad Mouhamad Wehbe, Rache..., Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts, 1/20/2014
  • A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.
    Lecia V. Sequist, Ariel Lopez-Chavez, Robert Charles Doebele, Jhanelle Elaine Gray, Wael A. Harb, Manuel R. Modiano, David Michael Jackman, Maria Quintos Baggstrom, Ak..., Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts, 1/1/2014
  • David E. Gerber, Toby Christopher Campbell, Paul Swanson, Ariel Lopez-Chavez, Lucas Wong, Afshin Dowlati, Amy Qin, Jan G. C. E., Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts., 1/1/2014
  • Join now to see all

Lectures

  • Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies, The CUSTOM trial experience. 
    Miami, FL - 1/1/2013
  • Tarceva and Avastin in Lung Cancer. 
    Boise, ID - 1/17/2012
  • An Evolving Treatment Strategy for Advanced Nonsquamous NSCLC with ALIMTA. 
    Hood River, OR - 1/8/2012
  • Join now to see all

Other

  • Cancer de Mama: Que es la neutropenia? 
    Lopez-Chavez, A., SisaludTV
    www.youtube.com
    1/26/2013
  • Cancer de Mama: Que es la neuropatia? 
    Lopez-Chavez, A., SisaludTV
    www.youtube.com
    1/26/2013
  • Cancer de Mama: Efectos adversos communes de la quimioterapia. 
    Lopez-Chavez, A., SisaludTV
    www.youtube.com
    1/26/2013
  • Join now to see all

Other Languages

  • Spanish

Hospital Affiliations